Genmab has agreed to acquire Merus, a clinical-stage biotechnology company with a late-stage breakthrough therapy asset called petosemtamab, which is in Phase III development.  Genmab will pay $97.00 per share in an all-cash transaction representing a transaction value of approximately $8 billion.   The proposed acquisition of Merus is expected to meaningfully accelerate Genmab’s shift to […]